17.82

0.22% -0.04

Viatris Inc (VTRS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Viatris Inc stock is traded at $17.82, with a volume of 10.03M. It is down -0.22% in the last 24 hours and up +9.80% over the past month. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Previous Close:

$17.86

Open:

$17.955

24h Volume:

10.03M

Relative Volume:

0.94

Market Cap:

$20.75B

Revenue:

$14.57B

Net Income/Loss:

$-296.50M

P/E Ratio:

-68.80

EPS:

-0.259

Net Cash Flow:

$1.64B

1W Performance:

+4.76%

1M Performance:

+9.80%

6M Performance:

+36.34%

1Y Performance:

+93.91%

1-Day Range:

$17.67

$18.07

1-Week Range:

$16.75

$18.07

52-Week Range:

$8.625

$18.07

Viatris Inc Stock (VTRS) Company Profile

Name

Viatris Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(724) 514-1465

Address

1000 MYLAN BOULEVARD, CANONSBURG

Employee

30,000

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

VTRS's Discussions on Twitter

Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTRS Viatris Inc	17.82	20.54B	14.57B	-296.50M	1.64B	-0.259
TAK Takeda Pharmaceutical Co Adr	17.75	55.69B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.28	43.77B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.71	36.19B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.93	32.25B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	524.70	26.29B	3.17B	1.29B	1.01B	27.09

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-09-26	Upgrade	UBS	Neutral → Buy
Jan-16-26	Upgrade	Argus	Hold → Buy
Dec-09-25	Initiated	Barclays	Overweight
Oct-15-25	Initiated	Truist	Buy
Jun-06-25	Initiated	Goldman	Neutral
Jul-19-24	Resumed	Jefferies	Buy
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-27-23	Upgrade	Jefferies	Hold → Buy
Nov-10-22	Upgrade	UBS	Sell → Neutral
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral
Oct-21-22	Resumed	Jefferies	Hold
Jun-14-22	Initiated	UBS	Sell
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-15-21	Initiated	Citigroup	Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Mar-08-21	Downgrade	Goldman	Buy → Neutral
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-05-21	Initiated	Argus	Hold
Dec-14-20	Initiated	Bernstein	Mkt Perform